Amid Supply Concerns, EU Approves Gilead’s Remdesivir
Despite Controversy, Blockbuster Status Predicted
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.
You may also be interested in...
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.